Skip to main content
Quest Diagnostics

Estimated SARS-CoV-2 Antibody Seroprevalence Trends and Relationship to Reported Case Prevalence From a Repeated, Cross-sectional Study in the 50 States and the District of Columbia, United States-October 25, 2020–February 26, 2022

Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022

Authors: Wiegand RE, Deng Y, Deng X, Lee A, Meyer WA 3rd, Letovsky S, Charles MD, Gundlapalli AV, MacNeil A, Hall AJ, Thornburg NJ, Jones J, Iachan R, Clarke KEN.

Citation: Lancet Reg Health Am. 2023 Feb;18:100403. doi: 10.1016/j.lana.2022.100403. Epub 2022 Dec 2.

Specialties: Infectious Disease, COVID-19, Immunology

Download key summary

Related content

Test FAQ
SARS CoV 2 Antibody Testing
Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.